Cited by 159Health Systems, Economic Evaluations, Quality of LifeDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis

Open access
Clarke, Philip M., Glasziou, Paul, Patel, Anushka, Chalmers, John, Woodward, Mark, Harrap, Stephen B., Salomon, Joshua A., on behalf of the ADVANCE Collaborative Group·2010·PLoS Medicine

Abstract

BACKGROUND: Diabetes imposes a substantial burden globally in terms of premature mortality, morbidity, and health care costs. Estimates of economic outcomes associated with diabetes are essential inputs to policy analyses aimed at prevention and treatment of diabetes. Our objective was to estimate and compare event rates, hospital utilization, and costs associated with major diabetes-related complications in high-, middle-, and low-income countries. METHODS AND FINDINGS: Incidence and history of diabetes-related complications, hospital admissions, and length of stay were recorded in 11,140 patients with type 2 diabetes participating in the Action in Diabetes and Vascular Disease (ADVANCE) study (mean age at entry 66 y). The probability of hospital utilization and number of days in hospital for major events associated with coronary disease, cerebrovascular disease, congestive heart failure, peripheral vascular disease, and nephropathy were estimated for three regions (Asia, Eastern Europe, and Established Market Economies) using multiple regression analysis. The resulting estimates of days spent in hospital were multiplied by regional estimates of the costs per hospital bed-day from the World Health Organization to compute annual acute and long-term costs associated with the different types of complications. To assist, comparability, costs are reported in international dollars (Int$), which represent a hypothetical currency that allows for the same quantities of goods or services to be purchased regardless of country, standardized on purchasing power in the United States. A cost calculator accompanying this paper enables the estimation of costs for individual countries and translation of these costs into local currency units. The probability of attending a hospital following an event was highest for heart failure (93%-96% across regions) and lowest for nephropathy (15%-26%). The average numbers of days in hospital given at least one admission were greatest for stroke (17-32 d across region) and heart failure (16-31 d) and lowest for nephropathy (12-23 d). Considering regional differences, probabilities of hospitalization were lowest in Asia and highest in Established Market Economies; on the other hand, lengths of stay were highest in Asia and lowest in Established Market Economies. Overall estimated annual hospital costs for patients with none of the specified events or event histories ranged from Int$76 in Asia to Int$296 in Established Market Economies. All complications included in this analysis led to significant increases in hospital costs; coronary events, cerebrovascular events, and heart failure were the most costly, at more than Int$1,800, Int$3,000, and Int$4,000 in Asia, Eastern Europe, and Established Market Economies, respectively. CONCLUSIONS: Major complications of diabetes significantly increase hospital use and costs across various settings and are likely to impose a high economic burden on health care systems.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1000236

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The risk of diabetic kidney disease is much higher in Asian countries than in Western countries due to different economic outcomes.

    “A study has found that the risk of diabetic kidney disease is much higher in Asian countries than in Western countries due to different economic outcomes (100).”
  • Patients with type 2 diabetes in Asian countries have a lower risk of coronary diseases than those from eastern Europe or Established Market Economies.

    “Interestingly, a study has indicated that patients with T2D in Asian countries have a lower risk of coronary diseases than those from eastern Europe or Established Market Economies (100).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 33 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [17]Jones AM 2000 Health econometrics. Culyer AJ Newhouse JP Handbook of health economics. Edition 1, volume 1, chapter 6 Amsterdam Elsevier 265 344
  2. [20]Rubin RJ Altman WM Mendelson DN 1994 Health expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 78 809A 809F 8157701

Cited by

Sorted by citations

Authors
Clarke, P. M., Glasziou, P., Patel, A., Chalmers, J., Woodward, M., Harrap, S. B., Salomon, J. A., & on behalf of the ADVANCE Collaborative Group
Affiliations
  • The University of Sydney (AU)
  • University of Oxford (GB)
  • The University of Melbourne (AU)
  • Harvard University (US)
Corresponding author
Clarke, Philip M.
Venue
PLoS Medicine
Published
2010-02-23
Volume
7
Issue
2
Pages
e1000236
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2015835669
Cited by
159
References
33
Citations by year
2026: 2 · 2025: 5 · 2024: 11 · 2023: 4 · 2022: 15 · 2021: 8 · 2020: 15 · 2019: 12 · 2018: 7 · 2017: 6 · 2016: 16 · 2015: 9 · 2014: 14 · 2013: 12 · 2012: 10
FWCI
25.66
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • University of Sydney
  • Servier
  • Medical Research Council
  • National Health and Medical Research Council (211086, 358395, 571122)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 2 diabetes, diabetes complications, hospital utilization, hospital costs, length of hospital stay, hospitalization rates, coronary disease, cerebrovascular disease, heart failure, peripheral vascular disease, diabetic nephropathy, international dollars, regional cost comparison, economic burden of diabetes, ADVANCE study, cost calculator, low- and middle-income countries, high-income countries, Asia, Eastern Europe
MeSH terms
Aged, Diabetes Mellitus, Type 2, Health Expenditures, Female, Hospitalization, Humans, Male, Middle Aged, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review